Skip to main content
Top
Published in: Rheumatology International 11/2021

01-11-2021 | Systemic Sclerosis | Observational Research

Esophageal dysmotility and lung disease in patients with systemic sclerosis: is there a possible association or correlation? A retrospective chart review

Authors: Navya Kuchipudi, Shweta Kishore, Chia-Ling Kuo, Santhanam Lakshminarayanan, Ranadeep Mandhadi

Published in: Rheumatology International | Issue 11/2021

Login to get access

Abstract

Objective

Our aim was to evaluate the relationship between esophageal dysmotility and lung disease by correlating the results of Echocardiogram and Pulmonary Function Test (PFT) with Esophageal Transit Study (ETT).

Methods

Charts of Systemic Sclerosis (SSc) patients fulfilling 2013 ACR/EULAR classification criteria seen in Rheumatology clinics were reviewed and their demographics, ETT result, PFT, and echocardiogram data were collected at baseline, years 1, 3, 5, and 10. Patients were divided based on their ETT status and were compared with respect to each variable using a two-sided two-sample t test for continuous variables and a Fisher’s exact test for categorical variables.

Results

130 patients were identified with either limited cutaneous SSc (109) or diffuse cutaneous SSc (21) with a mean age of 52.65 years. The mean DLCO was statistically worse in abnormal ETT patients [p value = 0.0004] as were the progression rates per year for DLCO at − 2.25 (p value = 0.019). Progression rate of FVC per year was statistically significant in the abnormal ETT group, although the mean value was not. The number of patients with abnormal PASP was not statistically different between the two groups (p values 0.104, 0.178, 0.653 at baseline, years 3 and 5, respectively).

Conclusion

The presence of esophageal dysmotility was associated with increased pulmonary involvement in the form of abnormal DLCO with worsening progression rates per year. There was no statistically significant difference in PASP and FVC between the two groups; however, the progression rate for FVC was worse in adjusted models.
Literature
1.
go back to reference Hasan O, Jessar M, Ashar M, Noordin S, Ahmad T (2017) Systemic sclerosis: clinical manifestations, anesthetic and orthopedic considerations in a patient. Int J Surg Case Rep 42:24–28CrossRef Hasan O, Jessar M, Ashar M, Noordin S, Ahmad T (2017) Systemic sclerosis: clinical manifestations, anesthetic and orthopedic considerations in a patient. Int J Surg Case Rep 42:24–28CrossRef
2.
go back to reference Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE (2009) Scleroderma prevalence: Demographic variations in a population-based sample. Arthritis Rheum 61:400–404CrossRef Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE (2009) Scleroderma prevalence: Demographic variations in a population-based sample. Arthritis Rheum 61:400–404CrossRef
3.
go back to reference Radstake TR, Gorlova O, Rueda B et al (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42:426–429 Radstake TR, Gorlova O, Rueda B et al (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42:426–429
4.
go back to reference De Martinis M, Ciccarelli F, Sirufo MM, Ginaldi L (2016) An overview of environmental risk factors in systemic sclerosis. Expert Rev Clin Immunol 12(4):465–478CrossRef De Martinis M, Ciccarelli F, Sirufo MM, Ginaldi L (2016) An overview of environmental risk factors in systemic sclerosis. Expert Rev Clin Immunol 12(4):465–478CrossRef
5.
go back to reference Schoenfeld SR, Castelino FV (2015) Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 41(2):237–248CrossRef Schoenfeld SR, Castelino FV (2015) Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 41(2):237–248CrossRef
6.
go back to reference Abu-Shakra M, Guillemin F, Lee P (1994) Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 24:29–39CrossRef Abu-Shakra M, Guillemin F, Lee P (1994) Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 24:29–39CrossRef
7.
go back to reference Lahcene M, Oumnia N, Matougui N, Boudjella M, Tebaibia A, Touchene B (2011) Esophageal involvement in scleroderma: clinical, endoscopic, and manometric features. ISRN Rheumatol , Article ID 325826, 5 Lahcene M, Oumnia N, Matougui N, Boudjella M, Tebaibia A, Touchene B (2011) Esophageal involvement in scleroderma: clinical, endoscopic, and manometric features. ISRN Rheumatol , Article ID 325826, 5
8.
go back to reference Maurer AH (2015) Gastroinestinal Motility, Part 1: Esophageal transit and gastric emptying. J Nucl Med 56:1229–1238PubMed Maurer AH (2015) Gastroinestinal Motility, Part 1: Esophageal transit and gastric emptying. J Nucl Med 56:1229–1238PubMed
9.
go back to reference Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809–1815CrossRef Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809–1815CrossRef
10.
go back to reference Soares RV, Forsythe A, Hogarth K, Sweiss NJ, Noth I, Patti MG (2011) Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. Arq Gastroenterol 48(2):91–97 Soares RV, Forsythe A, Hogarth K, Sweiss NJ, Noth I, Patti MG (2011) Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. Arq Gastroenterol 48(2):91–97
11.
go back to reference Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G (1998) Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158:1804–1808CrossRef Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G (1998) Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158:1804–1808CrossRef
12.
go back to reference Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J et al (2006) High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 27:136–142CrossRef Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J et al (2006) High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 27:136–142CrossRef
13.
go back to reference Patti MG, Tedesco P, Golden J, Hays S, Hoopes C, Meneghetti A et al (2005) Idiopathic pulmonary fibrosis: how often is it really idiopathic? J Gastrointest Surg 9:1053–1056CrossRef Patti MG, Tedesco P, Golden J, Hays S, Hoopes C, Meneghetti A et al (2005) Idiopathic pulmonary fibrosis: how often is it really idiopathic? J Gastrointest Surg 9:1053–1056CrossRef
14.
go back to reference Fahim A, Crooks M, Hart SP (2011) Gastroesophageal reflux and idiopathic pulmonary fibrosis: a review. Pulm Med 2011:634613 Fahim A, Crooks M, Hart SP (2011) Gastroesophageal reflux and idiopathic pulmonary fibrosis: a review. Pulm Med 2011:634613
15.
go back to reference Cantu E, 3rd, Appel JZ, 3rd, Hartwig MG, Woreta H, Green C, Messier R et al (2004) J. Maxwell Chamberlain Memorial Paper (Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease). Ann Thorac Surg 78:1142–1151 Cantu E, 3rd, Appel JZ, 3rd, Hartwig MG, Woreta H, Green C, Messier R et al (2004) J. Maxwell Chamberlain Memorial Paper (Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease). Ann Thorac Surg 78:1142–1151
16.
go back to reference Johnson DA, Drane WE, Curran J, Cattau EL Jr, Ciarleglio C, Khan A et al (1989) Pulmonary disease in progressive systemic sclerosis (A complication of gastroesophageal reflux and occult aspiration?). Arch Intern Med 149:589–593CrossRef Johnson DA, Drane WE, Curran J, Cattau EL Jr, Ciarleglio C, Khan A et al (1989) Pulmonary disease in progressive systemic sclerosis (A complication of gastroesophageal reflux and occult aspiration?). Arch Intern Med 149:589–593CrossRef
17.
go back to reference Lock G, Pfeifer M, Straub RH, Zeuner M, Lang B, Scholmerich J et al (1998) Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 93:341–345CrossRef Lock G, Pfeifer M, Straub RH, Zeuner M, Lang B, Scholmerich J et al (1998) Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 93:341–345CrossRef
18.
go back to reference Marie I, Dominique S, Levesque H, Ducrotté P, Denis P, Hellot MF, Courtois H (2001) Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 45(4):346–354CrossRef Marie I, Dominique S, Levesque H, Ducrotté P, Denis P, Hellot MF, Courtois H (2001) Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 45(4):346–354CrossRef
19.
go back to reference Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, Tatibouet S, Carmona L, Joven BE, Huq M, Proudman S, Nikpour M, and, (2017) Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheumatol 69:1067–1077CrossRef Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, Tatibouet S, Carmona L, Joven BE, Huq M, Proudman S, Nikpour M, and, (2017) Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheumatol 69:1067–1077CrossRef
21.
go back to reference Gual-Capllonch F, Teis A, Ferrer E et al (2018) Pulmonary vascular resistance versus pulmonary artery pressure for predicting right ventricular remodeling and functional tricuspid regurgitation. Echocardiography 35:1736–1745CrossRef Gual-Capllonch F, Teis A, Ferrer E et al (2018) Pulmonary vascular resistance versus pulmonary artery pressure for predicting right ventricular remodeling and functional tricuspid regurgitation. Echocardiography 35:1736–1745CrossRef
22.
go back to reference Denis P, Ducrotté P, Pasquis P, Lefrançois R (1981) Esophageal motility and pulmonary function in progressive systemic sclerosis. Respiration 42:21–24CrossRef Denis P, Ducrotté P, Pasquis P, Lefrançois R (1981) Esophageal motility and pulmonary function in progressive systemic sclerosis. Respiration 42:21–24CrossRef
23.
go back to reference Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G et al (2009) Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH- impedance monitoring. Am J Respir Crit Care Med 179:408–413CrossRef Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G et al (2009) Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH- impedance monitoring. Am J Respir Crit Care Med 179:408–413CrossRef
24.
go back to reference Vianna SR, Anne F, Kyle H, Nadera S, Imre N, Marco PG (2011) Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. Arq Gastroenterol 48(2):91–97CrossRef Vianna SR, Anne F, Kyle H, Nadera S, Imre N, Marco PG (2011) Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. Arq Gastroenterol 48(2):91–97CrossRef
Metadata
Title
Esophageal dysmotility and lung disease in patients with systemic sclerosis: is there a possible association or correlation? A retrospective chart review
Authors
Navya Kuchipudi
Shweta Kishore
Chia-Ling Kuo
Santhanam Lakshminarayanan
Ranadeep Mandhadi
Publication date
01-11-2021
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 11/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-021-04880-w

Other articles of this Issue 11/2021

Rheumatology International 11/2021 Go to the issue